Abbott Labs agrees to pay $1.6 billion to settle Depakote cases

Abbott Laboratories has agreed to pay $1.6 billion to settle claims that the company improperly marketed its neurological medication Depakote. The drug, approved to treat epilepsy, bipolar disorder and migraines, was allegedly marketed to treat schizophrenia, dementia and autism, a group of whistle-blower lawsuits claimed. The suits also said the company gave illegal kickbacks to doctors for talking about the off-label uses.  https://www.latimes.com/business/la-fi-abbott-depakote-20120507,0,7598749.story